June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Erythropoietin Protects Outer Blood–Retina Barrier in Experimental Diabetic Retina Through Up-regulating ZO-1 and occludin
Author Affiliations & Notes
  • Jingfa Zhang
    Department of Ophthalmology of Shanghai Tenth People’s Hospital, and Tongji Eye Institute, Tongji University School of Medicine, Shanghai, China
  • Chaoyang Zhang
    Department of Ophthalmology of Shanghai Tenth People’s Hospital, and Tongji Eye Institute, Tongji University School of Medicine, Shanghai, China
  • Qian Yang
    Department of Ophthalmology of Shanghai Tenth People’s Hospital, and Tongji Eye Institute, Tongji University School of Medicine, Shanghai, China
  • Weiye Li
    Department of Ophthalmology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States
  • Guo-Tong Xu
    Department of Ophthalmology of Shanghai Tenth People’s Hospital, and Tongji Eye Institute, Tongji University School of Medicine, Shanghai, China
  • Footnotes
    Commercial Relationships   Jingfa Zhang, None; Chaoyang Zhang, None; Qian Yang, None; Weiye Li, None; Guo-Tong Xu, None
  • Footnotes
    Support  This work was supported by National Natural Science Foundation of China (81570852, 81670867), and Shanghai Pujiang Program (15PJ1408700).
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5208. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Jingfa Zhang, Chaoyang Zhang, Qian Yang, Weiye Li, Guo-Tong Xu; Erythropoietin Protects Outer Blood–Retina Barrier in Experimental Diabetic Retina Through Up-regulating ZO-1 and occludin. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5208.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Blood-retinal barrier (BRB) breakdown is a major pathological characteristic of diabetic retinopathy. Erythropoietin (EPO) was protective in diabetic retinopathy. This study was to explore the possible protective mechanisms of EPO on outer BRB in early diabetic rat retinas.

Methods : Male Sprague-Dawley (SD) rats and ARPE-19 cell line were employed in this study. The SD rats were rendered diabetes with intraperitoneal injection of streptozotocin, followed by Intravitreal injection of EPO 2 hours later; 2 and 4weeks later, the permeability of outer BRB was examined using FITC-dextran leakage assay and the RPE-Bruch’s membrane choriocapillaris complex (RBCC) was isolated for protein detection. The glyoxal-treated ARPE-19 cells were incubated with or without EPO for 3 or 48 hours, and then the cells were studied for cell viability, cell death and permeability of RPE monolayer. The expressions of ZO-1, occludin, E-cadherin, etc. were examined.

Results : The leakage of FITC-dextran was detected mainly in outer nuclear layer in 2-week diabetic rat retinas and became more obvious in 4-week diabetic rat retinas. The leakage can be largely prevented in EPO-treated diabetic rats. The protein expressions of ZO-1 and occludin in RBCC remained unchanged in 2-week diabetic rats compared with that in normal control, but were decreased significantly in 4-week diabetic rats, which were reversed by EPO treatment. The in vitro study with ARPE-19 cells also confirmed above changes.

Conclusions : EPO could maintain outer BRB via up-regulating ZO-1 and occludin expressions in diabetic rats. The detailed mechanisms need further exploration.

*Dr. Weiye Li and Dr. Guo-Tong Xu are co-corresponding authors.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×